Passive lung-targeted drug delivery systems via intravenous administration

Pharmaceutical Development and Technology

Volumn 19, Issue 2, 2014, Pages 129-136

  Wei, Yumeng ^a   Zhao, Ling ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Evaluation; Liposomes; Lung targeted delivery systems; Microparticles; Nanoparticles

Indexed keywords

ALBUMIN; BIOMATERIAL; CARBOPLATIN; CEFTIOFUR; CHOLESTEROL; CISPLATIN; CLENBUTEROL; DEXAMETHASONE ACETATE; DIPYRIDAMOLE; DNA TOPOISOMERASE INHIBITOR; DRUG CARRIER; ENROFLOXACIN; ERYTHROMYCIN; GELATIN; ITRACONAZOLE; LEVOFLOXACIN; LIPOSOME; MICROSPHERE; NANOPARTICLE; OFLOXACIN; PACLITAXEL; PHOSPHOLIPID; POLYGLACTIN; POLYMER; POLYSORBATE; POLYSTYRENE; PROTIONAMIDE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YUANHUACINE;

AREA UNDER THE CURVE; DISPERSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRY POWDER; EMULSION; FIRST PASS EFFECT; FREEZE DRYING; HUMAN; HYDROPHOBICITY; LIPOSOMAL DELIVERY; LUNG; LUNG CANCER; LUNG DISEASE; LUNG TARGETED RUG DELIVERY SYSTEM; MICROCAPSULE; MICROENCAPSULATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHOSPHOLIPID BILAYER; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; TUBERCULOSIS; VASCULARIZATION; ZETA POTENTIAL;

ADMINISTRATION, INTRAVENOUS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84898644350     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.757782     Document Type: Review

References (70)

1. Chen JH, Wang L, Ling R, et al. Body distribution of nanoparticlecontaining adriamycin injected into the hepatic artery of hepatomabearing rats. Dig Dis Sci 2004;49:1170-3.
2. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albuminbound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17:1263-8.
3. Leucuta SE, Achim M, Risca R, Postescu ID. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. Stp Pharm Sci 2003;13:291-7.
4. Santhi K, Dhanaraj SA, Koshy M, et al. Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm 2000;26:1293-6.
5. Teng KY, Lu Z, Wientjes MG, Au JLS. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867-74.
6. Dailey LA, Kleemann E, Wittmar M, et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 2003;20:2011-20.
7. McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006;23:901-11.
8. Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-coglycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-6.
9. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005;85:227-34.
10. Videira MA, Botelho MF, Santos AC, et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002;10:607-13.
11. Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373-81.
12. Groneberg DA, Eynott PR, Döring F, et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 2002;57:55-60.
13. Groneberg DA, Witt C, Wagner U, et al. Fundamentals of pulmonary drug delivery. Resp Med 2003;97:382-7.
14. Ana G, Begona S, Carmen RL. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427-37.
15. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427-37.
16. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002;22:71S-9S.
17. Gessler T, Schmehl T, Olschewski H, et al. Aerosolized vasodilators in pulmonary hypertension. J Aerosol Med 2002;15:117-22.
18. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008;21:1-12.
19. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006;58:1061-75.
20. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801.
21. Shirzad A, Wilson HR, Raimar L. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008;60:863-75.
22. Huynh GH, Deen DF, Szoka Jr FC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006;110:236-59.
23. Chao P, Deshmukh M, Kutscher HL, et al. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs 2010;21:65-76.
24. Kutscher HL, Chao P, Deshmukh M, et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release 2010;143:31-7.
25. Wattendorf U, Merkle HP. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J Pharm Sci 2008;97:3655-69.
26. Zhang L, Zeng PY, Pan J, Lu WY. Optimized formulation and preparation process of LFY calcium alginate lung targeting microspheres. Chin J Pharmaceuticals 2004;35:150-3.
27. Huo DJ, Deng SH, Li LB, Ji J. Studies on the poly(lactic-coglycolic) acid microspheres of cisplatin for lung targeting. Int J Pharm 2005;289:63-7.
28. Lu B, Zhang JQ, Yang H. Lung-targeting microspheres of carboplatin. Int J Pharm 2003;265:1-11.
29. Hao ZH, Qu BH, Wang YL, et al. Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres. Drug Dev Ind Pharm 2011;37:1422-8.
30. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001;205:1-7.
31. Yang F, Wu SG, Pan YF, et al. Preparation and characteristics of erythromycin microspheres for lung targeting microspheres of erythromycin for lung targeting. Drug Dev Ind Pharm 2009;35: 639-45.
32. Tang S, Zhou Y, Li R, et al. Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation. J vet Pharmacol Therap 2007;30:443-50.
33. Sree H, Chandramouli R, Shobha R. Ofloxacin targeting to lungs by way of microspheres. Int J Pharm 2009;380:127-32.
34. Yan Z, Pei YY. Preparation, in vitro and in vivo evaluation of actively lung targetable microspheres for paclitaxel delivery. Chinese J Clin Pharm 2006;15:226-31.
35. Ying Y, Zhou SW, Tang JL, et al. Preparation of carboplatin microcapsules and tissue distribution in mice. China Pharmacy 2007;18:28-30.
36. Guo ZY, Zhao Wj, Zhang Q. Preparation and evaluation of lung targeting microspheres for protionamide in vitro and in vivo. Tuber Thor Tumor 2011;1:19-24.
37. Zhan ZJ, Fan CQ, Ding J, Yue JM. Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwa. Bioorg Med Chem 2005;13:645-55.
38. Zhang SX, Li XN, Zhang FH, et al. Preparation of yuanhuacine and relative daphne diterpeneesters from Daphne genkwa and structureactivity relationship of potent inhibitory activity against DNA topoisomerase I. Bioorg Med Chem 2006;14:3888-95.
39. Park BY, Min BS, Ahn KS, et al. Daphnane diterpene esters isolated from flower buds of Daphne genkwa induce apoptosis in human myelocytic HL-60 cells and suppress tumor growth in Lewis lung carcinoma (LLC)-inoculated mouse model. J Ethnopharmacol 2007;111:496-503.
40. Zhang SX, Gao XJ, Shen KH, et al. Evaluation of poly(d,l-lactideco- glycolide) microspheres for the lung-targeting of yuanhuacine, a novel DNA topoisomerase I inhibitor. J Drug Target 2009;17:286-93.
41. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29-40.
42. Kutscher HL, Chao P, Deshmukh M, et al. Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int J Pharm 2010;402:64-71.
43. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15.
44. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4:297-305.
45. Waser PG, Muller U, Kreuter J, et al. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradigraphy in mice. Int J Pharm 1987;39:213-27.
46. Zhang XK, Sun P, Bi R, et al. Targeted delivery of levofloxacinliposomes for the treatment of pulmonary inflammation. J Drug Target 2009;17:399-407.
47. Kusmic C, Picano E, Busceti CL, et al. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res 2000;47:510-14.
48. Cheng JI, Wen NA, Xiong F, et al. Characterization, lung targeting profile and therapeutic efficiency of dipyridamole liposomes. J Drug Target 2006;14:717-24.
49. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 2006;50:2946-50.
50. Rodrguez-Hernández MJ, Saugar J, Docobo-Pérez F, et al. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii. J Antimicrob Ch 2006;58:95-100.
51. Tewes F, Brillault J, Couet W, Olivier JC. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Control Release 2008;129:93-9.
52. Jiang QJ, Geng F, Zhang W. DepoFoam loading GD-DTPA targeting to lung: animal studies. Chinese J Oncoradiology 2009;2:25-9.
53. Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 1985;74:915-21.
54. Sada E, Kato S, Terashima M, Kawahara H. Effects of surface charges and cholesterol content on aminoacid permeabilities of small unilamllar vesicles. J Pharm Sci 1990;79:232-5.
55. Abra RM, Hunt CA, Lau DT. Liposome disposition in vivo. VI: Delivery to the lung. J Pharm Sci 1984;73:203-6.
56. Kim CK, Lee MK, Han JH, Lee BJ. Pharmacokinetics and tissue distribution of methotrexate after intravenous injection of differently charged liposome-entrapped methotrexate to rats. Int J Pharm 1994;108:21-9.
57. Jonah MM, Cerny EA, Rahman YE. Tissue distribution of EDTA encapsulated within liposomes of varying surface properties. Biochim Biophys Acta 1975;401:336-48.
58. Wang JS, Zhu JB, Shen W. Preparation of lung targeting azithromycin liposomes and its tissue distribution in mice. Acta Pharmaceutica Sinica 2005;40:274-8.
59. Zhao L, Ye Y, Li J, Wei YM. Preparation and the in vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. J Pharm Pharmacol 2011;63:80-6.
60. Zhao L, Wei YM, Zhong XD, et al. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 2009;49:989-96.
61. Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007;96:203-9.
62. Zhao L, Wei YM, Li W, et al. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and vivo evaluation. J Drug Target 2011;19:171-8.
63. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8.
64. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-46.
65. Betancourt T, Brown B, Peppas LB. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007;2:219-32.
66. Lowery AR, Gobin AM, Day ES, et al. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed 2006;1:149-54.
67. Flenniken ML, Liepold LO, Crowley BE, et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun 2005;28:447-9.
68. Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007;30:519-25.
69. Zhu L, Jia X, A YM, Zhang ZZ. In vivo distribution of gatifloxacin polybutylcyanoacrylate nanoparticles in mice. Chin J New Drugs 2010;19:60-3.
70. Shi Y, He F, Huang C, Tan ZN. Preparation and distribution in mice of itraconazole nanoparticles. Chin J Pharma 2010;41:106-10.